Roivant Sciences Ltd. (NASDAQ:ROIV) went down by -3.19% from its latest closing price compared to the recent 1-year high of $10.00. The company’s stock price has collected -13.88% of loss in the last five trading sessions. Barron’s reported on 02/28/22 that Moderna Faces Patent Lawsuit on Covid-19 Vaccine
Is It Worth Investing in Roivant Sciences Ltd. (NASDAQ :ROIV) Right Now?
Opinions of the stock are interesting as 9 analysts out of 9 who provided ratings for Roivant Sciences Ltd. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $13.13, which is $5.07 above the current price. ROIV currently public float of 440.82M and currently shorts hold a 3.72% ratio of that float. Today, the average trading volume of ROIV was 2.21M shares.
ROIV’s Market Performance
ROIV stocks went down by -13.88% for the week, with a monthly jump of 19.89% and a quarterly performance of 95.40%, while its annual performance rate touched 19.05%. The volatility ratio for the week stands at 4.88% while the volatility levels for the past 30 days are set at 6.95% for Roivant Sciences Ltd. The simple moving average for the period of the last 20 days is 0.24% for ROIV stocks with a simple moving average of 78.56% for the last 200 days.
Analysts’ Opinion of ROIV
Many brokerage firms have already submitted their reports for ROIV stocks, with JP Morgan repeating the rating for ROIV by listing it as a “Overweight.” The predicted price for ROIV in the upcoming period, according to JP Morgan is $7 based on the research report published on October 27th of the previous year 2022.
SVB Leerink, on the other hand, stated in their research note that they expect to see ROIV reach a price target of $6. The rating they have provided for ROIV stocks is “Outperform” according to the report published on May 23rd, 2022.
Cantor Fitzgerald gave a rating of “Overweight” to ROIV, setting the target price at $15 in the report published on April 29th of the previous year.
ROIV Trading at 22.62% from the 50-Day Moving Average
After a stumble in the market that brought ROIV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -15.00% of loss for the given period.
Volatility was left at 6.95%, however, over the last 30 days, the volatility rate increased by 4.88%, as shares surge +17.24% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +70.00% upper at present.
During the last 5 trading sessions, ROIV fell by -13.88%, which changed the moving average for the period of 200-days by +98.60% in comparison to the 20-day moving average, which settled at $8.54. In addition, Roivant Sciences Ltd. saw 6.38% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at ROIV starting from Venker Eric, who sale 24,037 shares at the price of $8.02 back on Jan 05. After this action, Venker Eric now owns 729,429 shares of Roivant Sciences Ltd., valued at $192,777 using the latest closing price.
Venker Eric, the President & COO of Roivant Sciences Ltd., sale 95,484 shares at $7.32 during a trade that took place back on Jan 03, which means that Venker Eric is holding 753,466 shares at $698,943 based on the most recent closing price.
Stock Fundamentals for ROIV
Equity return is now at value -77.70, with -46.20 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 3.58.